No Data
No Data
LIVZON PHARMA (01513.HK) spent 10 million yuan to repurchase 0.2783 million A-shares on February 14.
Gelonghui reported on February 14 that LIVZON PHARMA (01513.HK) announced the repurchase of 0.2783 million A shares for a cost of 10 million yuan on February 14, 2025, with a repurchase price of 35.72-36.27 yuan per share.
Hong Kong stocks fluctuated | CRO Concept stocks continued to surge in the morning, WUXI BIO (02269) and TIGERMED (03347) both rose over 9%.
In the early session, CRO Concept stocks continued to rise. As of the time of writing, WUXI BIO (02269) is up 9.59%, priced at 22.85 HKD; TIGERMED (03347) is up 9.09%, priced at 31.2 HKD; GENSCRIPT BIO (01548) is up 7.22%, priced at 11.88 HKD.
On February 13, LIVZON PHARMA (01513.HK) spent 20 million yuan to repurchase 0.5584 million shares of A-shares.
On February 13, Gelonghui reported that LIVZON PHARMA (01513.HK) announced the repurchase of 558,400 A-shares for 20 million yuan on February 13, 2025, at a price of 35.66-35.89 yuan per share.
Livzon Gets Nod to Trial Reflux Esophagitis Drug
Express News | Livzon Pharmaceutical - Received Notice of Drug Clinical Trial Approval Issued by Nmpa, Approving JP-1366 for Injection to Carry Out Clinical Trials
LIVZON PHARMA (01513.HK) spent 20 million yuan to buy back 0.5584 million A-shares on February 12.
On February 12, GELONGHUI reported that LIVZON PHARMA (01513.HK) announced a repurchase of 0.5584 million A shares at a cost of 20 million yuan on February 12, 2025, with a repurchase price per share ranging from 35.7 to 35.93 yuan.
The Market Doesn't Like What It Sees From Livzon Pharmaceutical Group Inc.'s (SZSE:000513) Earnings Yet